Cargando…

Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic

INTRODUCTION: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients. METHODS: We retrospectively analyzed a cohort of 401 patients with ILD and determined th...

Descripción completa

Detalles Bibliográficos
Autores principales: Guiot, J., Henket, M., Frix, A.N., Delvaux, M., Denis, A., Giltay, L., Thys, M., Gester, F., Moutschen, M., Corhay, J.L., Louis, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Respiratory Society. Published by Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501770/
https://www.ncbi.nlm.nih.gov/pubmed/32978099
http://dx.doi.org/10.1016/j.resinv.2020.08.006
Descripción
Sumario:INTRODUCTION: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients. METHODS: We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19. RESULTS: We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection. CONCLUSION: Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.